



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Garvey, et al**

Application No. **10/608,333**

Group Art Unit: **1614**

Filed: **June 30, 2003**

Examiner: **NOT YET ASSIGNED**

For: **Oxime And/Or Hydrozone Containing Nitrosated And/Or Nitrosylated Cyclooxygenase-2 Selective Inhibitors, Compositions and Methods Of Use**

Docket No: **102258.153 US1**

Honorable Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Please supply the undersigned attorney with a corrected filing receipt for the above-referenced application. The undersigned also respectfully requests that the Patent and Trademark Office records be amended to reflect the correction.

In reviewing the official Filing Receipt, we noted an error in that the last name of the first named inventor is incorrect. The correct name should read – Ramani R. Ranatunge--. A copy of the Assignment is enclosed which indicates the correct information. We are enclosing a copy of the filing receipt with the corrections highlighted.

Since the error was made by the U.S. Patent and Trademark Office, it is believed that no fee is required with regard to this Request; however, in the event that a fee is required, the Commissioner is authorized to charge such fee to Deposit Account No. 08-0219.

Respectfully submitted,

HALE AND DORR LLP

Edward D. Grieff
Registration No. 38,898

Date: October 7, 2003
HALE AND DORR LLP
1455 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Phone: 202-942-8400



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/608,333	06/30/2002	3514	1948	102258.153US		58	2

CONFIRMATION NO. 8773

FILING RECEIPT



OC000000010908302

24395
 HALE & DORR LLP
 THE WILLARD OFFICE BUILDING
 1455 PENNSYLVANIA AVE, NW
 WASHINGTON, DC 20004

Date Mailed: 09/23/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

* Ranatunga *

Ramani R. Ranatunga, Lexington, MA;
 David S. Garvey, Dover, MA;
 Stewart K. Richardson, Tolland, CT;

Assignment For Published Patent Application

NitroMed, Inc., Bedford, MA;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/392,044 06/28/2002

Foreign Applications


If Required, Foreign Filing License Granted: 09/17/2003

Projected Publication Date: 01/01/2004

Non-Publication Request: No

Early Publication Request: No

Title



Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).